Phuturdex › Diseases › Precursor lymphoblastic lymphoma/leukemia
Drugs in development · updated 30 October 2026
Precursor lymphoblastic lymphoma/leukemia: drugs in development
As of 30 October 2026 there are 234 active clinical trials (recruiting or ongoing, phases I–III) on 163 drugs for precursor lymphoblastic lymphoma/leukemia. 54 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 54 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II–III | 88 | NCT07297914 |
| FludarabineFludara, FLUDARABIN | II–III | 61 | NCT01949129 |
| BlinatumomabBlincyto® | II–III | 40 | NCT07297914 |
| MethotrexateJylamvo®, Reditrex® | II–III | 38 | NCT03117751 |
| DexamethasoneDexametasone, Dextenza | II–III | 37 | NCT03117751 |
| CytarabineAra-C, Cytosine Arabinoside | II–III | 32 | NCT03117751 |
| VincristineVincristin, Oncovin [vincristine] | II–III | 30 | NCT03117751 |
| MelphalanEvomela®, Hepzato® | III | 19 | NCT05457556 |
| Mercaptopurine6-Mercaptopurine, Mecaptopurine | II–III | 19 | NCT03117751 |
| TacrolimusEnvarsus XR, Prograf® | III | 19 | NCT05457556 |
| EtoposideAvopef®, Etopophos Preservative Free® | II–III | 16 | NCT03117751 |
| PegaspargasePegylated-asparaginase, PEG asparaginase | II–III | 16 | NCT03117751 |
| VenetoclaxVentoclax, Venclexta® | II–III | 16 | NCT06764238 |
| BusulfanBusulphan, Busulfex® | II–III | 15 | NCT01949129 |
| Mycophenolate MofetilMycophenolate, Cellcept | III | 15 | NCT05457556 |
Sorted by most advanced phase and number of active trials. Showing 15 of 109 drugs.
All 163 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Precursor T-cell lymphoblastic leukemia 61 drugs
- Precursor B-cell lymphoblastic leukemia 31 drugs
- Lymphoma 252 drugs
- Burkitt lymphoma 113 drugs
- T-cell lymphoma 74 drugs
- Acute biphenotypic leukaemia 80 drugs
- Peripheral T-cell lymphoma 71 drugs
- Anaplastic large-cell lymphoma 36 drugs
- Immunoblastic lymphadenopathy 32 drugs
- Cutaneous T cell lymphoma 46 drugs
- Leukemia 153 drugs
- Acute myeloid leukemia 314 drugs
Broader categories
- Hematologic Diseases 57 drugs
- Lymphatic system disease 20 drugs
- Immunoproliferative disorder 16 drugs
- Immune System Diseases 54 drugs
- Lymphoproliferative disorders 51 drugs
- Lymphoid leukemia 18 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D054198 “Precursor Cell Lymphoblastic Leukemia-Lymphoma”. Prevalence: Orphanet.